EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY-NC 4.0

Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial

Jie-Eun Lee, Seung Hee Yu, Sung Rae Kim, Kyu Jeung Ahn, Kee-Ho Song, In-Kyu Lee, Ho-Sang Shon, In Joo Kim, Soo Lim, Doo-Man Kim, Choon Hee Chung, Won-Young Lee und 26 weitere

Diabetes & Metabolism Journal · 31.07.2024 · 48 (4) · 730-739

DOI: 10.4093/dmj.2023.0077 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 31.07.2024. Verfasst von Jie-Eun Lee und 37 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeo…. Hauptthemen laut MEDLINE: Atorvastatin, Metformin, Diabetes Mellitus, Type 2, Dyslipidemias. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Daewoong Pharmaceutical Company, HK inno.N Corp..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is well known that a large number of patients with diabetes also have dyslipidemia, which significantly increases the risk of cardiovascular disease (CVD). This study aimed to evaluate the efficacy and safety of combination drugs consisting of metformin and atorvastatin, widely used as therapeutic agents for diabetes and dyslipidemia.

Methods

This randomized, double-blind, placebo-controlled, parallel-group and phase III multicenter study included adults with glycosylated hemoglobin (HbA1c) levels >7.0% and 100 and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinMetforminDiabetes Mellitus, Type 2DyslipidemiasDrug Therapy, CombinationGlycated HemoglobinHypoglycemic AgentsCholesterol, LDLHumansMaleFemaleDouble-Blind MethodMiddle AgedAgedTreatment OutcomeAdult

Stichwörter der Autor:innen

AtorvastatinDiabetes mellitusDyslipidemiasMetformin

Substanzen

AtorvastatinMetforminGlycated HemoglobinHypoglycemic AgentsCholesterol, LDLhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University School of Medicine, Uijeongbu, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.
  • Department of Endocrinology and Metabolism, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Konkuk University Medical Center, Seoul, Korea.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

Förderung

  • Daewoong Pharmaceutical Company
  • HK inno.N Corp.

Zitieren

APA

Lee, J. E., Yu, S. H., Kim, S. R., Ahn, K. J., Song, K. H., Lee, I. K., Shon, H. S., Kim, I. J., Lim, S., Kim, D. M., Chung, C. H., Lee, W. Y., Lee, S. H., Kim, D. J., Cho, S. R., Jung, C. H., Jeon, H. J., Lee, S. H., Park, K. Y., …, & Lee, M. K. (2024). Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial. Diabetes & Metabolism Journal, 48(4), 730-739. https://doi.org/10.4093/dmj.2023.0077

Vancouver

Lee JE, Yu SH, Kim SR, Ahn KJ, Song KH, Lee IK, et al. Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial. Diabetes & Metabolism Journal. 2024;48(4):730-739. doi:10.4093/dmj.2023.0077

BibTeX
@article{Lee2024,
  author = {Lee, Jie-Eun and Yu, Seung Hee and Kim, Sung Rae and Ahn, Kyu Jeung and Song, Kee-Ho and Lee, In-Kyu and Shon, Ho-Sang and Kim, In Joo and Lim, Soo and Kim, Doo-Man and Chung, Choon Hee and Lee, Won-Young and Lee, Soon Hee and Kim, Dong Joon and Cho, Sung-Rae and Jung, Chang Hee and Jeon, Hyun Jeong and Lee, Seung-Hwan and Park, Keun-Young and Rhee, Sang Youl and Kim, Sin Gon and Park, Seok O and Kim, Dae Jung and Kim, Byung Joon and Lee, Sang Ah and Kim, Yong-Hyun and Kim, Kyung-Soo and Seo, Ji A and Nam-Goong, Il Seong and Lee, Chang Won and Kim, Duk Kyu and Kim, Sang Wook and Cho, Chung Gu and Kim, Jung Han and Kim, Yeo-Joo and Yoo, Jae-Myung and Min, Kyung Wan and Lee, Moon-Kyu},
  title = {Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial},
  journal = {Diabetes & Metabolism Journal},
  year = {2024},
  volume = {48},
  number = {4},
  pages = {730--739},
  doi = {10.4093/dmj.2023.0077}
}
Kostenlos starten →